Agomab Therapeutics (AGMB) Current Leases (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Current Leases of $289846.8 for Q4 2025, down 0.64% year-over-year from $291726.5 in Q4 2024, and down 0.64% quarter-over-quarter from $291726.5 in Q4 2024.
Agomab Therapeutics (AGMB) Current Leases (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Current Leases history runs 2 years deep, the most recent figure standing at $289846.8 for Q4 2025.
- In Q4 2025, Current Leases fell 0.64% year-over-year to $289846.8; the TTM figure through Dec 2025 stood at $289846.8 (down 0.64% YoY), while the FY2025 annual figure was $289846.8, down 1.91% from the prior year.
- Current Leases for Q4 2025 stood at $289846.8, down from $291726.5 in the prior quarter.
- The five-year high for Current Leases was $291726.5 in Q4 2024, with the low at $289846.8 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Agomab Therapeutics | 7.20 Mn | -250.38 Mn | - | 266,180.86 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 289,846.84 |
| Dec 31, 2024 | 291,726.54 |